2 weeks Ago By Defense World Staff
KLP Kapitalforvaltning AS purchased a new position in shares of SpringWorks Therapeutics, Inc. ( NASDAQ:SWTX – Free Report ) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 12,600 shares of the company’s stock, valued at approximately $455,000.
Other hedge funds have also recently bought and sold shares of the company. AlphaQuest LLC increased its stake in shares of SpringWorks Therapeutics by 70.2% in the fourth quarter.
AlphaQuest LLC now owns 1,004 shares of the company’s stock valued at $36,000 after purchasing an additional 414 shares during the period. Venturi Wealth Management LLC acquired a new stake in SpringWorks Therapeutics in the 4th quarter valued at approximately $45,000. KBC Group NV raised its stake in SpringWorks Therapeutics by 59.
1% during the 4th quarter. KBC Group NV now owns 2,634 shares of the company’s stock valued at $95,000 after acquiring an additional 978 shares in the last quarter. US Bancorp DE boosted its position in SpringWorks Therapeutics by 56.
0% during the 4th quarter. US Bancorp DE now owns 4,336 shares of the company’s stock worth $157,000 after acquiring an additional 1,556 shares during the period. Finally, Quantbot Technologies LP bought a new position in shares of SpringWorks Therapeutics in the third quarter worth $147,000.
Analyst Upgrades and Downgrades Several equities research analysts recently weighed in on SWTX shares. Evercore ISI upped their price objective on shares of SpringWorks Therapeutics from $60.00 to $65.
00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. HC Wainwright reaffirmed a “buy” rating and issued a $74.00 price target on shares of SpringWorks Therapeutics in a research note on Friday, February 21st.
Wedbush reiterated an “outperform” rating and set a $81.00 price objective on shares of SpringWorks Therapeutics in a research note on Thursday, February 20th. Finally, Guggenheim cut their target price on SpringWorks Therapeutics from $80.
00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, SpringWorks Therapeutics currently has a consensus rating of “Buy” and an average target price of $73.
20. Insider Activity In other SpringWorks Therapeutics news, insider Bhavesh Ashar sold 1,016 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $61.
19, for a total transaction of $62,169.04. Following the completion of the sale, the insider now directly owns 62,053 shares of the company’s stock, valued at approximately $3,797,023.
07. This represents a 1.61 % decrease in their ownership of the stock.
The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink . Also, CEO Saqib Islam sold 49,000 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $54.
24, for a total transaction of $2,657,760.00. Following the completion of the transaction, the chief executive officer now owns 954,869 shares of the company’s stock, valued at approximately $51,792,094.
56. The trade was a 4.88 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . In the last 90 days, insiders sold 440,766 shares of company stock worth $24,402,956. Insiders own 7.
61% of the company’s stock. SpringWorks Therapeutics Trading Down 9.2 % Shares of NASDAQ SWTX opened at $39.
09 on Friday. The firm has a 50-day moving average of $48.71 and a two-hundred day moving average of $39.
94. The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of -11.
23 and a beta of 0.79. SpringWorks Therapeutics, Inc.
has a twelve month low of $28.21 and a twelve month high of $62.00.
SpringWorks Therapeutics ( NASDAQ:SWTX – Get Free Report ) last released its earnings results on Thursday, February 20th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.
66) by ($0.38). The business had revenue of $61.
55 million for the quarter, compared to analyst estimates of $60.53 million. SpringWorks Therapeutics had a negative net margin of 134.
73% and a negative return on equity of 46.74%. As a group, research analysts predict that SpringWorks Therapeutics, Inc.
will post -2.05 earnings per share for the current year. SpringWorks Therapeutics Profile ( Free Report ) SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer.
Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. Featured Articles Five stocks we like better than SpringWorks Therapeutics Canada Bond Market Holiday: How to Invest and Trade Archer Aviation’s Africa Deal Could Boost ACHR Stock Following Congress Stock Trades Are Short Sellers Wrong About These 3 Semiconductor Stocks? Russell 2000 Index, How Investors Use it For Profitable Trading Boeing Gets $50B in March Orders—Is BA Stock a Buy Now? Want to see what other hedge funds are holding SWTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SpringWorks Therapeutics, Inc.
( NASDAQ:SWTX – Free Report ). Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
